Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-07), Neuland Laboratories's 12-1 Month Momentum % is 48.02%.
The industry rank for Neuland Laboratories's 12-1 Month Momentum % or its related term are showing as below:
NSE:NEULANDLAB's 12-1 Month Momentum % is ranked better than 87.59% of 1015
companies
in the Drug Manufacturers industry
Industry Median: -11.87
vs NSE:NEULANDLAB: 48.02
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Neuland Laboratories 12-1 Month Momentum % Related Terms
NSE:NEULANDLAB vs ZTS: 12-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuland Laboratories 12-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Neuland Laboratories's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuland Laboratories (NSE:NEULANDLAB) has a 12-1 Month Momentum % of 48.02% as of Aug. 07, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Neuland Laboratories and its competitors. According to the industry distribution chart, Neuland Laboratories ranks #126 out of 1015 companies in the Drug Manufacturers industry, placing it in the top 12.4%.
Is Neuland Laboratories' 12-1 Month Momentum % too high?
Neuland Laboratories' current 12-1 Month Momentum % is 48.02%. Based on the distribution chart, Neuland Laboratories ranks #126 out of 1015 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Neuland Laboratories has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' 12-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Neuland Laboratories ranks #126 out of 1015 companies for 12-1 Month Momentum %. This places Neuland Laboratories in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Drug Manufacturers company?
A good 12-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Neuland Laboratories and its competitors. Neuland Laboratories's current 12-1 Month Momentum % is 48.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹16,238.49, compared to a current price of ₹21,543.00 — trading 32.7% above its estimated fair value. The current 12-1 Month Momentum % is 48.02%. Neuland Laboratories' overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current 12-1 Month Momentum % is 48.02% as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued.
The current stock price of ₹21,543.00 is trading 32.7% above its estimated GF Value™ of ₹16,238.49.
GuruFocus considers Neuland Laboratories to be Significantly Overvalued.
Key valuation signals for NSE:NEULANDLAB:
12-1 Month Momentum %: 48.02%
GF Value™: ₹16,238.49 vs. price of ₹21,543.00 (32.7% above fair value)
No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
87GF Score
Get the complete analysis for NSE:NEULANDLAB
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NEULANDLAB has been successfully added to your 
